Podcasts about biotech

Dr. Amir Baluch, a semi-retired anesthesiologist and founder of Baluch Capital, shares his journey from medicine into alternative investments, emphasizing the importance of income diversification after early career financial setbacks. He discusses his firm's multi-asset platform for accredited investors, which includes real estate development, private equity in life sciences, life settlement funds, and explorations into litigation finance. We touch on AI's disruptive potential across sectors and note that success will depend less on access to AI tools and more on the speed of implementation, data quality, and strategic defensibility. We discuss...  Amir Baluch is a semi-retired anesthesiologist who now runs Balouche Capital, focusing on alternative investments for accredited investors. Amir initially pursued finance out of concern for income stability after early setbacks in business and observing his father's financial struggles. Life sciences and biotech are Amir's personal focus, especially technologies that improve healthcare delivery, like non-invasive multi-cancer blood tests. Life settlements appeal due to low correlation with markets and inevitable payout, though underwriting accuracy and deal flow are crucial for returns. Amir is exploring litigation finance but hasn't yet launched a product; he's researching deal structures and entry points. Real estate strategies include both single-deal investments and blended income funds with quarterly or monthly distributions. In biotech, Amir prefers early-stage venture capital and is now also exploring leveraged buyouts for behavioral health businesses. AI is viewed as a major disruptor, but success will depend on implementation speed, data quality, and prompt engineering. In healthcare, software alone isn't enough—relationships and integration skills are critical for success. Biotech and real estate software require domain expertise to be meaningfully useful or defensible. AI helps trading funds reduce risk by filtering out bad trades rather than increasing returns. Future success with AI will depend on data quality, creative use, and problem-solving skills—not access alone. Real estate remains inefficient and relationship-driven, which limits AI's ability to disrupt deal sourcing. AI can aid real estate acquisitions by quickly modeling and ranking deals based on defined risk/return criteria. Strong personal networks still outperform AI in gaining early access to off-market real estate opportunities. Today's Panelists: Kirk Chisholm | Innovative Wealth Diana Perkins | Trading With Diana Follow on Facebook: https://www.facebook.com/moneytreepodcast Follow LinkedIn: https://www.linkedin.com/showcase/money-tree-investing-podcast Follow on Twitter/X: https://x.com/MTIPodcast For more information, visit the show notes at https://moneytreepodcast.com/from-medicine-to-alternative-investments-dr-amir-baluch-728 

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with Hella Kohlhof, CSO at Immunic. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Hella, covering: How the 'waste of two molecules' led to the spin-out creation of Immunic Therapeutics. The perfect blend of a founding team willing to split responsibility, learn and have a go. Ending up as a Nasdaq-listed company via a reverse merger... and all the new challenges that came with it. Immunic's divide-and-conquer global outsourcing strategy, while retaining tight control. Examples of how geopolitical issues have impacted a biotech's growth. Hella leads the Immunic's scientific strategy, including mode of action research, preclinical studies, and biomarker development. Dr. Kohlhof brings deep expertise in immunology, oncology, and drug development, with previous roles at 4SC AG, where she led preclinical and clinical projects. She holds a doctorate in biology from Ludwig Maximilians University of Munich and completed her postdoc at the Helmholtz Centre, focusing on B cell development. She holds several patents, has co-authored numerous publications, and is a regular speaker at scientific and industry events. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating! Molecule to Market is also sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

Quang Pham went from being a 10-year-old refugee airlifted out of Vietnam to becoming a Marine pilot, and the CEO of a NASDAQ-listed biotech company. In this conversation, he shares the exact lessons that guided each transition.   Key insight: On decision-making: “As a young officer, we were taught to make decisions… there's not enough time to consult with everybody. You gotta make a decision to keep moving and then adjust along the way.” This became his foundational leadership principle across sectors. On capital discipline: “In the private sector and entrepreneurial world, resources are scarce… you have to treat it with the utmost respect and spend it wisely.” Military spending habits do not translate to startups. On performance and promotion: “You work hard, but you have to produce results.” Early in his corporate career, he assumed promotions would come automatically. They did not. On defining success: “You have to follow and pursue what makes you happy. Not what your family or your culture or society wants.” As a Vietnamese refugee, choosing the military was going against all cultural expectations. On raising capital without pedigree: “I lacked the skills to present to venture capitalists… so I spent a lot of time at Toastmasters picking up new speaking skills.” Within 90 days of leaving his corporate job, he secured venture funding as a first-time CEO. On pitch strategy: “You have to get to the key points… in the first seven or ten minutes, if not sooner.” Investors have limited attention. He focused his pitch on buyer, payment frequency, and execution, not theoretical market size. On cold outreach: “It was just three sentences. Who I was, what my company did, something about our common [background].” This approach led to two successful VC rounds. On leadership transitions: “I knew that I had the skills and the backing and that the baton had to be passed… the company flourished and I was then just a shareholder.” Founders must be willing to step aside to scale. On AI and decision-making: “There is somebody making decisions for AI, the decision to use AI, the decision to pay for AI… at the end of the day, we still need entrepreneurs and leaders.” This episode offers practical reflections for those navigating leadership transitions, capital formation, and decision-making in complex, resource-constrained settings.   Get Quang's new book here: https://quangxpham.com/   Here are some free gifts for you:   Overall Approach Used in Well-Managed Strategy Studies free download: www.firmsconsulting.com/OverallApproach   McKinsey & BCG winning resume free download: www.firmsconsulting.com/resumepdf   Enjoying this episode? Get access to sample advanced training episodes here: www.firmsconsulting.com/promo

Gigi Robinson grew up with Ehlers-Danlos syndrome, a disease that turns your joints into overcooked spaghetti. Instead of letting it sideline her, she built a career out of telling the truth about invisible illness. We talk about what it takes to grow up faster than you should, why chronic illness is the worst unpaid internship, and how she turned her story into a business. You'll hear about her days schlepping to physical therapy before sunrise, documenting the sterile absurdity of waiting rooms, and finding purpose in the mess. Gigi's not interested in pity or polished narratives. She wants you to see what resilience really looks like, even when it's ugly. If you think you know what an influencer does, think again. This conversation will challenge your assumptions about work, health, and what it means to be seen.RELATED LINKSGigi Robinson Website: https://www.gigirobinson.comLinkedIn: https://www.linkedin.com/in/gigirobinsonInstagram: https://www.instagram.com/itsgigirobinsonTikTok: @itsgigirobinsonA Kids Book About Chronic Illness: https://akidsco.com/products/a-kids-book-about-chronic-illnessFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Daphne Koller, CEO of insitro and cofounder of Coursera, joins Leadership Next to unpack a bold idea: Just as calculus revolutionized our understanding of physics, AI could do the same for biology. In this episode, Koller explains how insitro is blending biology and machine learning to unlock new treatments for diseases like ALS and fatty liver. She also opens up about her leap from academia to entrepreneurship, the ethical challenges of data collection, and why the future of medicine lies in personalized, AI-driven care. Plus, her take on why humans and machines must work in tandem to drive meaningful innovation. 

Treg-based cell therapies are nearing a clinical proof-of-concept inflection point, but in an environment that has dramatically shifted with the advent of CAR T therapies for autoimmune diseases. On the latest BioCentury This Week podcast, BioCentury's analysts discuss what these cell therapies need to show to be relevant in the fast-changing I&I world, and which types of indications may best suit the cells' unique profile.The team also explores the biotech sector's ongoing struggle to capture the interest of generalist investors, and what the next major theme might be to draw them back.The analysts then break down the key provisions in the recently passed U.S. reconciliation tax bill, highlighting the positive and negative developments, as well as the missed opportunities for the industry. This episode of BioCentury This Week was sponsored by IQVIA Biotech. View full story: https://www.biocentury.com/article/656376#biotech #biopharma #pharma #lifescience #CellTherapy #TregTherapy #CAR_T00:01 - Sponsor Message: IQVIA Biotech01:19 - Treg Inflection Point10:57 - Biotech's Next Big Story22:36 - Tax Bill ConsequencesTo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text

President Trump announcing 25% tariffs on goods from Japan and South Korea, and a handful of other countries are also in the crosshairs. What it means for markets, as they back off record levels. Plus biotech stocks have been on the upswing since April. Can the trend continue? We talk to one top analyst to find out.Fast Money Disclaimer

We love to hear from our listeners. Send us a message. This week's episode is one from the road, recorded in front of a live audience in Boston's Seaport neighborhood during the BIO conference (special thanks to MasterControl for making it happen). Amber Salzman, Ph.D., CEO of Epicrispr Biotechnologies (aka 'Epic Bio') explains how epigenetic editing is revolutionizing genetic medicine by controlling gene expression, without cutting DNA like traditional CRISPR technologies. Amber talks about FSHD, a progressive muscular dystrophy, how the company raised $68 million in Series B funding despite challenging market conditions, her partnership with Springbok Analytics for AI analysis of MRI images, working with a CDMO to manufacture a new treatment modality, and navigating the FDA during a time of disruption. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

Today's guests are Dan Rasmussen, founder of Verdad Advisers, and D.A. Wallach, a venture capital investor for Time BioVentures and an acclaimed recording artist. Pharrell Williams discovered D.A.'s band Chester French and signed the group to Interscope Records. In today's episode, Dan & D.A. discuss the current state of biotech, the impact of AI on healthcare, and the role of innovative treatments in transforming patient care. The three also touch on the shifting narrative of private equity, tax strategies, venture capital returns, and much more. (0:00) Starts (1:02) D. A.'s journey from musician to investor (7:30) Dan on the state of biotech (19:14) Opportunities and challenges in healthcare and biotech (33:16) Private equity market dynamics (41:30) Public vs. private markets and venture capital returns analysis (59:54) Opportunities in international markets (1:09:00) Tax strategies (1:16:39) Potential biotech investments (1:19:00) Global investment trends ----- Follow Meb on X, LinkedIn and YouTube For detailed show notes, click here To learn more about our funds and follow us, subscribe to our mailing list or visit us at cambriainvestments.com ----- Follow The Idea Farm: X | LinkedIn | Instagram | TikTok ----- Interested in sponsoring the show? Email us at Feedback@TheMebFaberShow.com ----- Past guests include Ed Thorp, Richard Thaler, Jeremy Grantham, Joel Greenblatt, Campbell Harvey, Ivy Zelman, Kathryn Kaminski, Jason Calacanis, Whitney Baker, Aswath Damodaran, Howard Marks, Tom Barton, and many more.  ----- Meb's invested in some awesome startups that have passed along discounts to our listeners. Check them out here!  ----- Editing and post-production work for this episode was provided by The Podcast Consultant (https://thepodcastconsultant.com). Learn more about your ad choices. Visit megaphone.fm/adchoices

Karl and Erum bring on Dr. Alexander Titus, a commissioner on the National Security Commission on Emerging Biotechnology, to explore the exciting and challenging intersections of biotechnology and policy. Alexander shares his experiences from his unique journey across academia, government, and industry, diving into the role of biosecurity, the potential of synthetic biology, and the emerging convergence of tech and bio. They discuss ambitious projects like de-extincting the woolly mammoth, advances in biodefense, and the impacts of AI on biotech innovation. It's a conversation that sheds light on how cutting-edge biotech could shape the future and the necessary balance between innovation and ethical responsibility.Grow Everything brings the bioeconomy to life. Hosts Karl Schmieder and Erum Azeez Khan share stories and interview the leaders and influencers changing the world by growing everything. Biology is the oldest technology. And it can be engineered. What are we growing?Learn more at⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠www.messaginglab.com/groweverything⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠Chapters:00:00:00 - Behind the Scenes of Bureaucracy00:00:30 - Democracy's Turning Point00:02:23 - A Fiery Day in Prospect Park00:04:20 - How Spaces Shape Our Health00:08:35 - Enter Alexander Titus: Biosecurity Visionary00:10:13 - Biotech: The New Face of National Defense00:15:09 - Where Tech and Policy Collide00:23:10 - The Future of Biosecurity Unfolds00:28:02 - Bold Science vs. Ethical Boundaries00:30:24 - Robotics Meets Biotech: What's Next?00:33:29 - Hard Lessons from Cross-Industry Giants00:35:49 - Innovation Clashes with Red Tape00:36:11 - The Power of Expertise in Shaping Policy00:42:26 - Biotech's Hidden Environmental Risks00:45:42 - The Commission's Bold Path Forward00:48:45 - Parting Thoughts: What Lies AheadTopics Covered: biotech, biosecurity, national security commission on emerging biotechnology, policyEpisode Links: ⁠The Wild Life of Our Bodies by Robb Dunn ⁠ ⁠Geerat Vermeij⁠ ⁠BTO - Biological Technologies Office of DARPA⁠⁠ Bioeconomy.XYZ⁠ ⁠The Nobel Turing Challenge⁠ ⁠Range by David Epstein⁠ ⁠NSCEB Interim Report⁠ ⁠AI Safety Institute⁠ ⁠The Echo Wife by Sara Gailey⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Have a question or comment? Message us here:Text or Call (804) 505-5553⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Instagram⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ /⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠TikTok⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ /⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Twitter⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ /⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠LinkedIn⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ /⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Youtube⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ /⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠GrowEverything website⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Email: groweverything@messaginglab.comMusic by: NihiloreProduction by: Amplafy Media

Nick Johnston, a former biotech banker and entrepreneur, founded Alis Biosciences to solve one of the biggest challenges that every biotech might face on its road – how to maximize shareholders' value when a public-listed company loses market confidence? Alis creates a safety netfor shareholders by giving the trapped capital back and supporting the company with promising science to get back on track. Since its launch in 2025, Alis has identified over 300 small-cap biotech companies representing nearly $30 billion in underutilized capital, and has already completed successful take-private deals that delivered over 90% of uncommitted cash back to investors - faster and more efficiently than traditional liquidation processes. In this episode, you will hear about:Why Nick started Alis Biosciences, and how his background in healthcare banking shaped the model.How stagnation in capital markets leaves early-stage biotech companies in limbo and how Alis offers an innovative path forward.Why it still makes sense to invest in new science, and how Alis distinguishes between value traps and scientific opportunity.

The promise of generative AI in pharma and biotech is huge, but it's also fraught with complexity, especially when it comes to integrating these systems into highly regulated environments. From monitoring evolving guidelines to balancing operational efficiency and data integrity, the journey from hype to real-world impact is filled with both opportunity and skepticism.In this episode, David Brühlmann sits down with Abhijeet Satwekar, Innovation Manager at Merck Healthcare's Global Analytical Development. Abhijeet has spent years on the front lines of digital transformation in the biotech sector, and his current mission: implementing generative AI for regulatory guideline monitoring, without giving the quality team a collective heart attack. He offers a no-nonsense roadmap for biotech leaders looking to streamline compliance, harness AI potential, and future-proof their operations.Here are three reasons you should hit play on this episode:From Proof of Concept to Real-World Implementation: Discover how Abhijeet's team moved beyond early excitement to tackle regulatory, IT, and data privacy requirements, carving a safe and compliant path for bringing generative AI tools into GxP and GMP-adjacent workflows.Human-in-the-Loop Isn't Optional: Learn why user training, prompt engineering, and close collaboration between scientists and AI are essential for extracting meaningful (and accurate) insights, especially in environments where routine and regulation reign supreme.ROI and Regulation - The Balancing Act: Hear candid perspectives on measuring the return on investment for new digital tools, addressing skeptics closer to manufacturing, and why the real game-changer might just be a community-driven, industry-wide approach to regulatory acceptance.Wondering how to unlock GenAI's full potential - or just avoid the common pitfalls? Dive into this episode for practical strategies, cautionary tales, and actionable insights from someone who's actually navigated the compliance minefield.Bring AI into your pipeline with confidence, clarity, and compliance.Connect with Abhijeet Satwekar:LinkedIn: https://www.linkedin.com/in/abhijeetsatwekarNext step:Book a free consultation to help you get started on any questions you may have about bioprocessing development: https://bruehlmann-consulting.com/callDevelop bioprocessing technologies better, faster, at a fraction of the cost with our 1:1 Strategy Call: The quickest and easiest way to excel biotech technology development. Book your call at https://stan.store/SmartBiotechSupport the show

Today's show:It's another blockbuster panel of insiders, as Alex sits down with Astasia Myers from Felicis, Matt Turck from First Mark Capital, and D.A. Wallach of Time BioVentures. AI is reshaping early-stage investing, with startups raising record-setting rounds adn chasing $100B+ markets. Meanwhile, biotech faces a “Great Depression” as public markets stay shut, putting added pressure on private capital. In healthcare, AI-powered virtual doctors promise to bring world-class medical advice to everyone, while fertility tech could revolutionize IVF by automating embryo handling and slashing costs. Hear our VC experts exclusive thoughts on these trends and much more!Timestamps:(2:21) The post-Q2 landscape and everyone's immediate reactions(05:00) Why biotech is in a “Great Depression,” even for AI companies!(9:36) CLA - Get started with CLA's CPAs, consultants, and wealth advisors now at https://claconnect.com/tech(12:14) Overpriced vs. high-performing: Do high prices ALWAYS mean low expected returns and vice versa?(14:50) Mega markets: how AI is different from past software shifts(18:58) Everyone's companies are CRUSHING IT: why genAI has crazy tailwinds right now(20:33) Sentry - New users get 3 months free of the Business plan (covers 150k errors). Go to http://sentry.io/twist and use code TWIST(21:46) Product-market fit and revenue durability in AI(24:29) Marketing and community development for early stage founders(25:14) AI advancements in humor, avatars, and healthcare(29:30) Public - Take your investing to the next level with Public. Build a multi-asset portfolio and earn 4.1% APY on your cash—with no fees or minimums. Start now at public.com/twist.(30:45) Healthcare innovation and AI foundation models(35:37) AI differentiation, OpenAI valuation, and infrastructure companies(43:08) User experience in LLMs and AI inference costs(51:21) AI healthcare applications and founding team trends(56:28) Hiring trends, burn rates, and outsourcing in biotech(1:01:51) Government investment in biotech and the European AI ecosystem(1:06:43) Academic founders and the Felicis Fellows program(1:09:10) Recent exits and the outlook for the upcoming quarters(1:12:27) Innovations in fertility treatments and prenatal testing(1:15:51) Summary of bullish trends and future outlook(1:16:14) Closing remarks and future check-in plansSubscribe to the TWiST500 newsletter: https://ticker.thisweekinstartups.comCheck out the TWIST500: https://www.twist500.comSubscribe to This Week in Startups on Apple: https://rb.gy/v19fcpFollow Lon:X: https://x.com/lonsFollow Alex:X: https://x.com/alexLinkedIn: ⁠https://www.linkedin.com/in/alexwilhelmFollow Jason:X: https://twitter.com/JasonLinkedIn: https://www.linkedin.com/in/jasoncalacanisThank you to our partners:(9:36) CLA - Get started with CLA's CPAs, consultants, and wealth advisors now at https://claconnect.com/tech(20:33) Sentry - New users get 3 months free of the Business plan (covers 150k errors). Go to http://sentry.io/twist and use code TWIST(29:30) Public - Take your investing to the next level with Public. Build a multi-asset portfolio and earn 4.1% APY on your cash—with no fees or minimums. Start now at public.com/twistGreat TWIST interviews: Will Guidara, Eoghan McCabe, Steve Huffman, Brian Chesky, Bob Moesta, Aaron Levie, Sophia Amoruso, Reid Hoffman, Frank Slootman, Billy McFarlandCheck out Jason's suite of newsletters: https://substack.com/@calacanisFollow TWiST:Twitter: https://twitter.com/TWiStartupsYouTube: https://www.youtube.com/thisweekinInstagram: https://www.instagram.com/thisweekinstartupsTikTok: https://www.tiktok.com/@thisweekinstartupsSubstack: https://twistartups.substack.comSubscribe to the Founder University Podcast: https://www.youtube.com/@founderuniversity1916

Today we talk the end of quarter performance for quarter two of 2025. How did you do? We also cover a wide range of economic and market topics, beginning with the complexities of investing in artificial intelligence, lessons on succession planning, leadership transitions, and the importance of understanding demographic and power dynamics in both politics and investing. We note that large-cap growth, tech, and industrials led Q2 performance, while energy and real estate lagged. Mounting debt, rising delinquencies, and wage garnishment were cited as signs of economic stress, especially among younger and lower-income Americans, but the U.S. is still regarded as one of the best places to live. Today we discuss...  AI emerges as a hot investing theme, but it's difficult to get meaningful public equity exposure to the trend. We talks lessons for business owners on succession planning and the difference between operators and visionaries. You should invest in yourselves, learn how to work with AI, and become irreplaceable in the workforce. They conclude that unlike past tech revolutions, understanding AI is more about mindset, prompting skills, and creative application than simply buying stock exposure. Warren Buffett can be both the greatest investor of all time and underperform over the last 25 years. Buffett's investment challenges are partly due to managing massive capital, but he also strayed from his original strategy. Buffett should have retired decades ago and left day-to-day decisions to others. This is a parallel between aging leaders in investing and aging politicians who refuse to step down. The Baby Boomer generation is described as unintentionally draining economic resources through demographic trends. Understanding leadership transitions and generational shifts is crucial for evaluating companies and markets. Q2 market performance shows large-cap growth outperforming small-cap and value stocks. Sectors like industrials, communications, and tech led, while energy, real estate, and healthcare lagged. High beta, momentum, and pure growth factors outperformed, while high dividend and low volatility underperformed. Treasury bonds, especially international, were among the best-performing fixed income assets. Precious metals like gold, silver, and uranium led commodities; agricultural products like corn and wheat lagged. Many top-performing countries are printing money, boosting markets, despite geopolitical or structural issues. Biotech investing is highly complex due to multiple layers of science, regulation, and operational risk. Investors don't need to invest in every trendy sector—understanding is more important than participation. Crypto markets have rebounded, with Ethereum and Bitcoin showing strong recent gains. The "Magnificent Seven" tech stocks have mixed performance, with Apple and Tesla notably underperforming. The market is entering a historically strong July–August window, buoyed by trade optimism. U.S.–China relations show signs of improvement, including mutual resource access. Buy Now, Pay Later services are beginning to impact credit scores and consumer financial stability. Over 2.3 million households are delinquent on mortgage payments, with foreclosures up 34%. Renters face growing pressure, with 21% behind on payments and eviction filings surging. Mounting debt burdens are fueling disillusionment among younger Americans, increasing support for socialism. Inflation has cooled from 9% in 2022 to 2.4% in April 2025. Despite challenges, the U.S. is still viewed as one of the best places to live. For more information, visit the show notes at https://moneytreepodcast.com/end-of-quarter-performance-725  Today's Panelists: Kirk Chisholm | Innovative Wealth Douglas Heagren | ProCollege Planners Follow on Facebook: https://www.facebook.com/moneytreepodcast Follow LinkedIn: https://www.linkedin.com/showcase/money-tree-investing-podcast Follow on Twitter/X: https://x.com/MTIPodcast  

#89: My guest today is Alejandro Pérez Heinze who is a composer, Flamenco guitarist, audio engineer, Kontakt instrument producer, and audio educator based in Mexico. He has worked on a wide variety of projects including Kontakt instrument production on Kena: Bridge of Spirits, also working with Austin Wintory on projects such as Thai Cave Rescue, and composing on games such as Frogreign.   In this episode, we talk about Alejandro's extremely broad career path, starting off as an electric guitarist, switching over to Flamenco guitar, going to college for Biotech, and switching to audio production and engineering. We also talk about his unique skillset and how it landed him work in the game audio industry, and so much more.   Find Alejandro here: Website: https://www.alejandrophz.com/ LinkedIn: https://www.linkedin.com/in/alejandrophz/ Instagram: https://www.instagram.com/alejandro.phz/ SoundCloud: https://soundcloud.com/alejandrophz   Get info on The Game Industry Professional, my flagship course that teaches you how to make a great living in game audio here: bit.ly/gameindustrypro

Synopsis: Longevity isn't just about living longer—it's about living better. In this insightful episode of Biotech 2050, host Alok Tayi sits down with Sergey Jakimov, Founding Partner at LongeVC, to unpack what it really takes to invest in the future of healthspan. Blending his experience as a medtech entrepreneur, rare disease patient, and venture capitalist, Sergey shares why LongeVC focuses on practical, science-backed longevity solutions rather than hype-driven moonshots. He explains why aging isn't a disease, how diagnostics differ from therapeutics in venture ROI, and what makes AI drug discovery a pivotal unlock in modern biotech. The conversation also explores the rise of pet longevity, the role of lifestyle in aging, and how LongeVC grew from a €20M experiment to a high-performing fund now raising $250M for Fund Two—all with zero write-offs. For founders, funders, and anyone curious about the intersection of biotech, aging, and real-world outcomes, this episode offers an honest, no-fluff look at building the future of longevity—one evidence-based investment at a time. Biography: Sergey Jakimov is a founding partner of LongeVC, a venture capital fund supporting early-stage biotech and longevity-focused founders that are changing the world. He is a serial entrepreneur, having co-founded 3 deep-tech ventures and raised more than $40 million in venture funding for his own ventures and as an entrepreneur in residence. He has worked with several other early-stage companies in the therapeutics space on fundraising, IP protection, and clinical trial strategies, focusing on early treatments in cardiovascular, oncology, and neurodegenerative spaces. He is also a visiting lecturer to several universities on venture capital and intellectual property rights, and he co-authored a master's program in Technology Law for the Riga Graduate School of Law. Since 2018, he has co-founded medical tech startup Longenesis, a cutting-edge company that unlocks the hidden value of biomedical data and accelerates novel drug treatment & discovery. In 2020 he co-founded LongeVC, and in 2021, he co-founded the Longevity Science Foundation - a non-profit organization advancing the field of human longevity by funding research and development of medical technologies to extend the healthy human lifespan. He holds a BSc in International Affairs from Rīga Stradiņš University and two MScs in Political Science and Government and Law and Finance from Central European University and Riga Graduate School of Law, respectively. He was named Forbes Latvia 30 Under 30 in technology and healthcare in 2020.

In this episode of Let's Combinate, Archana shares her insights on the critical factors involved in designing clinical trials, from phase one safety profiling to pivotal phase three trials. She also discusses the importance of patient diversity, the ethical considerations in clinical research, and the future of clinical trials, including decentralized trials and the use of advanced technologies. The conversation highlights the intricate balance between maintaining rigorous scientific standards and adapting to new methodologies to enhance patient recruitment and data integrity. Time Stamps: 00:00 Welcome and Introduction 00:28 Understanding Clinical Trial Design 00:58 Phases of Clinical Trials 02:27 Oncology Trials and Patient Pathways 05:00 Protocol Design and Regulatory Considerations 08:40 Patient Preferences and Vendor Selection 18:53 Types of Clinical Trials 23:01 Understanding BA and BE Studies 24:39 Clinical Coordination of BA/BE Studies 25:15 Infrastructure and Emergency Management in Clinical Trials 26:19 Addressing Mistrust in Clinical Trials 29:54 Ensuring Diversity in Clinical Trials 32:41 The Rise of Decentralized Clinical Trials 39:06 Challenges and Solutions in Decentralized Trials 42:49 Technology and Regulation in Clinical Trials 47:28 Final Thoughts and Contact InformationArchana Sah is a Clinical development thought leader with extensive (30 years) experience and passion for developing medicines for patients having led and contributed to 15 FDA/EMEA drug approvals including Tecentriq® in multiple indications and combinations, Alecensa®, Polivy®, Hemlibra®, Gazyva®, Pixuvri®. She has held various global positions within Biotech, Big pharma, CRO including Genentech/Roche, Bayer Oncology, Johnson & Johnson, ICON, and two Oncology biotech start up companies. She has also worked in healthcare technology as the Senior Vice President of Digital and Decentralized Solutions at Medable Inc. She is now an independent strategy consultant and Board Advisor and provides strategic advisory services to pharma, biotechs, digital healthtech software companies, venture firms in clinical development and operations as well as on leveraging innovative patient centered digital health technologies in a fit for purpose approach to improve diversity, access and efficiencies within the healthcare ecosystem. She has been honored as Top20 women in immuno oncology drug development and featured in PharmaFEATURES on Oncology drug development and Digital Health technology.She has routinely led several industry collaboration consortiums. She is the co-founding chair and member of Society for Clinical Research Sites Oncology Board and chaired the Annual Oncology Summits. She is a current Mentor for the CancerX Moonshot program dedicated to revolutionizing advancements in cancer care, clinical trials, patient support, biotech & pharma and drive integration of digital tools in oncology. She serves on the Leadership Council for Decentralized Trials and Research Alliance(DTRA) and as their Evidence/Publications Librarian. She also serves as an Advisor to American Cancer Society Cancer Action Network (ACS CAN) and is a reviewer for the international Journal of the American Cancer Society "Cancer". Invited advisor and keynote/speaker at several industry conferences.Contact: archana.sah@aspharmaadvisors.comSubhi Saadeh is a Quality Professional and host of Let's Combinate. With a background in Quality, Manufacturing Operations, and R&D, he has worked in large Medical Device and Pharma organizations to support the development and launch of hardware devices, disposable devices, and combination products for vaccines, generics, and biologics.Subhi currently serves as the International Committee Chair for the Combination Products Coalition (CPC), is a member of ASTM Committee E55, and has served on AAMI's Combination Products Committee.

Bridging the gap between academia and industry isn't easy—but it's essential for innovation. In this episode, hosts Elaine Hamm, PhD, and James Zanewicz, JD, LLM, RTTP, explore how biotech startups and academic institutions can break down silos and build stronger partnerships. From shared resources and mutual funding opportunities to culture shifts and advisory support, they reveal how deeper engagement between innovation hubs and industry players can lead to better science, better business, and better outcomes. In this episode, you'll learn: Why understanding each other's goals and processes is key to successful startup–university collaborations. How universities can help startups find funding, credibility, and critical talent—and what startups offer in return. Actionable tips for building long-term, win-win partnerships that drive innovation forward. Whether you're spinning out of a lab or investing in university research, this episode will give you new strategies to connect and collaborate with purpose. Links: Connect with Elaine Hamm, PhD, and James Zanewicz, JD, LLM, RTTP, and learn about Tulane Medicine Business Development, the School of Medicine, and the National Primate Research Center. Connect with Katie Acuff, JD, MBA, Lauren Jardell, and Ellen Palmintier, JD, RN. Tune in to our previous episode on Boards of Directors and Scientific Advisory Boards. Connect with Ian McLachlan, BIO from the BAYOU producer. Check out BIO on the BAYOU and make plans to attend October 28 & 29, 2025. And click here to apply for a startup pitch slot. Learn more about BIO from the BAYOU - the podcast. Bio from the Bayou is a podcast that explores biotech innovation, business development, and healthcare outcomes in New Orleans & The Gulf South, connecting biotech companies, investors, and key opinion leaders to advance medicine, technology, and startup opportunities in the region.

Episode Description:If you've ever wondered what happens when a Bronx-born pediatric nurse with stage 4 colon cancer survives, raises a kid, becomes a policy shark, and fights like hell for the ignored, meet Vanessa Ghigliotty. She's not inspirational. She's a bulldozer. We go way back—like pre-Stupid Cancer back—when there was no “young adult cancer movement,” just a handful of pissed-off survivors building something out of nothing. This episode is personal. Vanessa and I built the plane while flying it. She fought to be heard, showed up in chemo dragging her kid to IEP meetings, and never stopped screaming for the rest of us to get what we needed. We talk war stories, progress, side-eyeing advocacy fads, TikTok activism, gatekeeping, policy wins, and why being loud is still necessary. And yeah—she's a damn good mom. Probably a better one than you. You'll laugh. You'll cry. You'll want to scream into a pillow. Come for the nostalgia. Stay for the righteous anger and iced coffee.RELATED LINKSVanessa on LinkedInColorectal Cancer Alliance: Vanessa's StoryZenOnco Interview with VanessaFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Ever feel like you're drowning in an ocean of constantly shifting regulatory guidelines? The world of biotech is a whirlwind of evolving standards, making compliance not just a headache, but sometimes the stumbling block between life-changing therapies and the patients who need them. But what if artificial intelligence could turn regulatory chaos into your biggest competitive advantage?In this episode, David Brühlmann sits down with Abhijeet Satwekar, Innovation Manager at Merck KGaA's Global Analytical Development. Abhijeet shares how he's pioneering the use of generative AI, not as a hype machine, but as a practical, transformative tool for regulatory compliance in biotech. With over a decade navigating analytics, digitalization, and collaborative tech adoption at a major pharma leader, Abhijeet knows what it takes to connect industry stakeholders, harness new technologies, and turn business operations into streamlined, value-generating systems.Here are three reasons you won't want to miss this episode:Generative AI as a Compliance Powerhouse: Discover how AI is being harnessed to analyze, extract, and compare complex regulatory requirements across different countries, cutting through ambiguous language and shifting specifications - so you don't have to.Reducing Regulatory Bottlenecks: The days of manually reconciling guideline documents and updating baselines with every regulatory change are numbered. Learn how generative AI accelerates multi-guideline comparison, saving teams countless hours and reducing the risk of costly errors and delays.A Blueprint for Digital Transformation: Abhijeet reveals how Merck is moving from proof-of-concept to operational reality, building collaborative teams that bridge IT, analytics, regulatory, and quality to bring valuable digital tools into daily practice.Curious if your team could automate away regulatory headaches? Listen in and get inspired to tackle your toughest compliance challenges - before your competitors do.Connect with Abhijeet Satwekar:LinkedIn: https://www.linkedin.com/in/abhijeetsatwekarNext step:Book a free consultation to help you get started on any questions you may have about bioprocessing development: https://bruehlmann-consulting.com/callDevelop bioprocessing technologies better, faster, at a fraction of the cost with our 1:1 Strategy Call: The quickest and easiest way to excel biotech technology development. Book your call at https://stan.store/SmartBiotechSupport the show

What if a mouse could help shape the future of cancer treatment? In this episode of Sounds of Science, host Mary Parker speaks with Julia Schüler, DVM, PhD, Research Director and Therapeutic Area Lead for Oncology at Charles River. Julia shares how patient-derived xenograft (PDX) models—often described as “avatars” of human tumors—are transforming preclinical oncology research. From preserving tumor heterogeneity to improving translational relevance, PDX models are accelerating the discovery of more effective, personalized therapies. Tune in as we explore how these advanced models are driving innovation across the drug development pipeline—from target discovery to clinical trial design.Show NotesPDX Tumor Organoids : A New Tool in Drug Discovery Testing Realm Organoids: Some Assembly Required Patient-Derived Xenografts- PDX Models 3D Tumor Models In Vitro PDX Assays 

In this week's MBA Admissions podcast we began by discussing some of the recent activity on LiveWire, which is now becoming quieter as we move into the summer season. We then continued our discussion on the recent U.S. Government decisions as they pertain to international MBA students; Harvard appears to have won a recent decision in their fight with the U.S. Government in terms of being able to enroll international students.. Graham highlighted Clear Admit's summer series of webinars, which focuses on top MBA programs' admissions essays, which will be attended by more than 20 of the top MBA programs. The first event in the series includes Berkeley / Haas, Cornell / Johnson, Dartmouth / Tuck, Duke / Fuqua and UPenn / Wharton. Signups are here: https://bit.ly/mbaessay0725. Graham then noted two admissions tips; the first focuses on the importance of post MBA career goals, the second, part of Clear Admit's “Myth Busters” series, discusses the differences between targeting Round 1 and Round 2.. We continue our series of Adcom Q&As, which is a yearly series where we interview the admissions leaders at all the top MBA programs; this week we have Q&As from NYU / Stern and Georgetown / McDonough.. Finally, Graham highlighted a Real Humans alumni spotlight focusing on an alum from IESE working at PwC.. For this week, for the candidate profile review portion of the show, Alex selected three ApplyWire entries:. This week's first MBA admissions candidate has a 329 GRE score and a 3.4 GPA. They are working in the biotech sector, and plan to remain in that sector, post MBA. They want to do investment banking in the short term.. This week's second MBA candidate has a 3.86 GPA but has not taken the GMAT or GRE yet. They are also focused on the health care sector.. The final MBA candidate is from South Korea and has 10 years of experience in the tech sector, focusing on AI and robotics. They have a 685 GMAT score. This episode was recorded in Kansas City, Missouri and Cornwall, England. It was produced and engineered by the fabulous Dennis Crowley in Philadelphia, USA. Thanks to all of you who've been joining us and please remember to rate and review this show wherever you listen!

We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Jennifer Hawks Bland, CEO of NewYorkBIO, shares insights on New York State's life sciences ecosystem while reflecting on her journey from Capitol Hill to biotech advocacy. Her experiences in politics, law, and biopharma government affairs uniquely positions her to navigate complex policy challenges while creating opportunities for biotech upstarts across New York and beyond. Jennifer also highlights key programs, capabilities, and funding on offer to early-stage biotech companies.  This episode of the Business of Biotech is brought to you by Ecolab Life Sciences. Learn more at https://www.ecolab.com.Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

With growing FDA bottlenecks and regulatory changes, this episode explores how biotechs are looking beyond borders by rethinking trials, embracing real-world data, and finding new global pathways to bring therapies to life. Small Biotechs, Big Decisions is a limited podcast series exploring the challenges and opportunities facing emerging biotech companies, hosted by Daniel Chancellor, VP of Thought Leadership at Norstella, and Claire Riches, VP of Clinical Solutions at Citeline, a leading provider of life sciences data and insights. View the video series and find out more information here: https://www.citeline.com/biotech

Top officials gave updated damage assessments on the Trump administration's historic bunker bust of Iran's nuclear program. On Thursday, both the President and U.S. Defense Secretary Hegseth pushed back on media reports downplaying the efficacy of the strikes, emphasizing this was a "highly successful mission." FOX News Sunday anchor Shannon Bream joins to discuss the latest updates on Iran's nuclear capabilities, New York's Mayoral Democratic primary, and a Supreme Court ruling on funding to Planned Parenthood. Malaria kills around 600,000 people each year according to the World Health Organization, with mosquitoes largely responsible for spreading this deadly disease. Futurist Jamie Meltz, author of “Superconvergence: How the Genetics, Biotech, and AI Revolutions Will Transform our Lives,” joins the podcast to explore the scientific possibility of editing mosquitoes' DNA in order to eliminate or genetically modify the entire species, while warning of the ethical and ecological risks when altering complex natural systems. Don't miss the good news with Tonya J. Powers. Plus, commentary by Brian Kilmeade, Host of One Nation with Brian Kilmeade and The Brian Kilmeade Show. Photo Credit: AP Learn more about your ad choices. Visit podcastchoices.com/adchoices

Have you ever been cut off mid-sentence, had your idea hijacked, or been completely misunderstood with no chance to recover? If you're someone who already finds speaking up challenging, these moments can feel devastating. In this episode, I'm sharing exactly how to reclaim your voice and communicate with unshakeable confidence. What I'm Covering: Why interruptions hit socially reserved people especially hard (and why it's not about the value of what you're saying) The real psychology behind why people interrupt—from enthusiasm to power plays My proven strategies for recovering in-the-moment when someone cuts you off or misunderstands you How to have follow-up conversations that prevent future interruptions without damaging relationships My In-the-Moment Recovery Framework: Stay Centered and Reclaim the Floor - Confident phrases to get your voice back Use Your Body Language - How to project confidence even when you're feeling rattled Address Misunderstandings Immediately - Scripts for clarifying without being defensive Bridge Back to Your Point - Techniques for returning to your original contribution  **   Don't even know where to begin in improving your interpersonal skills? Are you ready to leave social stress behind and go from where you are to where you want to be? Book a Social Strategy Session HERE  Free Guide: The Social Skills Playbook Have a question that needs an answer. Email me at Hello@SocialConfidencePro.com   LinkedIn Instagram TikTok

My fellow pro-growth/progress/abundance Up Wingers,Once-science-fiction advancements like AI, gene editing, and advanced biotechnology have finally arrived, and they're here to stay. These technologies have seemingly set us on a course towards a brand new future for humanity, one we can hardly even picture today. But progress doesn't happen overnight, and it isn't the result of any one breakthrough.As Jamie Metzl explains in his new book, Superconvergence: How the Genetics, Biotech, and AI Revolutions will Transform our Lives, Work, and World, tech innovations work alongside and because of one another, bringing about the future right under our noses.Today on Faster, Please! — The Podcast, I chat with Metzl about how humans have been radically reshaping the world around them since their very beginning, and what the latest and most disruptive technologies mean for the not-too-distant future.Metzl is a senior fellow of the Atlantic Council and a faculty member of NextMed Health. He has previously held a series of positions in the US government, and was appointed to the World Health Organization's advisory committee on human genome editing in 2019. He is the author of several books, including two sci-fi thrillers and his international bestseller, Hacking Darwin.In This Episode* Unstoppable and unpredictable (1:54)* Normalizing the extraordinary (9:46)* Engineering intelligence (13:53)* Distrust of disruption (19:44)* Risk tolerance (24:08)* What is a “newnimal”? (13:11)* Inspired by curiosity (33:42)Below is a lightly edited transcript of our conversation. Unstoppable and unpredictable (1:54)The name of the game for all of this . . . is to ask “What are the things that we can do to increase the odds of a more positive story and decrease the odds of a more negative story?”Pethokoukis: Are you telling a story of unstoppable technological momentum or are you telling a story kind of like A Christmas Carol, of a future that could be if we do X, Y, and Z, but no guarantees?Metzl: The future of technological progress is like the past: It is unstoppable, but that doesn't mean it's predetermined. The path that we have gone over the last 12,000 years, from the domestication of crops to building our civilizations, languages, industrialization — it's a bad metaphor now, but — this train is accelerating. It's moving faster and faster, so that's not up for grabs. It is not up for grabs whether we are going to have the capacities to engineer novel intelligence and re-engineer life — we are doing both of those things now in the early days.What is up for grabs is how these revolutions will play out, and there are better and worse scenarios that we can imagine. The name of the game for all of this, the reason why I do the work that I do, why I write the books that I write, is to ask “What are the things that we can do to increase the odds of a more positive story and decrease the odds of a more negative story?”Progress has been sort of unstoppable for all that time, though, of course, fits and starts and periods of stagnation —— But when you look back at those fits and starts — the size of the Black Plague or World War II, or wiping out Berlin, and Dresden, and Tokyo, and Hiroshima, and Nagasaki — in spite of all of those things, it's one-directional. Our technologies have gotten more powerful. We've developed more capacities, greater ability to manipulate the world around us, so there will be fits and starts but, as I said, this train is moving. That's why these conversations are so important, because there's so much that we can, and I believe must, do now.There's a widely held opinion that progress over the past 50 years has been slower than people might have expected in the late 1960s, but we seem to have some technologies now for which the momentum seems pretty unstoppable.Of course, a lot of people thought, after ChatGPT came out, that superintelligence would happen within six months. That didn't happen. After CRISPR arrived, I'm sure there were lots of people who expected miracle cures right away.What makes you think that these technologies will look a lot different, and our world will look a lot different than they do right now by decade's end?They certainly will look a lot different, but there's also a lot of hype around these technologies. You use the word “superintelligence,” which is probably a good word. I don't like the words “artificial intelligence,” and I have a six-letter framing for what I believe about AGI — artificial general intelligence — and that is: AGI is BS. We have no idea what human intelligence is, if we define our own intelligence so narrowly that it's just this very narrow form of thinking and then we say, “Wow, we have these machines that are mining the entirety of digitized human cultural history, and wow, they're so brilliant, they can write poems — poems in languages that our ancestors have invented based on the work of humans.” So we humans need to be very careful not to belittle ourselves.But we're already seeing, across the board, if you say, “Is CRISPR on its own going to fundamentally transform all of life?” The answer to that is absolutely no. My last book was about genetic engineering. If genetic engineering is a pie, genome editing is a slice and CRISPR is just a tiny little sliver of that slice. But the reason why my new book is called Superconvergence, the entire thesis is that all of these technologies inspire, and influence, and are embedded in each other. We had the agricultural revolution 12,000 years ago, as I mentioned. That's what led to these other innovations like civilization, like writing, and then the ancient writing codes are the foundation of computer codes which underpin our machine learning and AI systems that are allowing us to unlock secrets of the natural world.People are imagining that AI equals ChatGPT, but that's really not the case (AI equals ChatGPT like electricity equals the power station). The story of AI is empowering us to do all of these other things. As a general-purpose technology, already AI is developing the capacity to help us just do basic things faster. Computer coding is the archetypal example of that. Over the last couple of years, the speed of coding has improved by about 50 percent for the most advanced human coders, and as we code, our coding algorithms are learning about the process of coding. We're just laying a foundation for all of these other things.That's what I call “boring AI.” People are imagining exciting AI, like there's a magic AI button and you just press it and AI cures cancer. That's not how it's going to work. Boring AI is going to be embedded in human resource management. It's going to be embedded just giving us a lot of capabilities to do things better, faster than we've done them before. It doesn't mean that AIs are going to replace us. There are a lot of things that humans do that machines can just do better than we are. That's why most of us aren't doing hunting, or gathering, or farming, because we developed machines and other technologies to feed us with much less human labor input, and we have used that reallocation of our time and energy to write books and invent other things. That's going to happen here.The name of the game for us humans, there's two things: One is figuring out what does it mean to be a great human and over-index on that, and two, lay the foundation so that these multiple overlapping revolutions, as they play out in multiple fields, can be governed wisely. That is the name of the game. So when people say, “Is it going to change our lives?” I think people are thinking of it in the wrong way. This shirt that I'm wearing, this same shirt five years from now, you'll say, “Well, is there AI in your shirt?” — because it doesn't look like AI — and what I'm going to say is “Yes, in the manufacturing of this thread, in the management of the supply chain, in figuring out who gets to go on vacation, when, in the company that's making these buttons.” It's all these little things. People will just call it progress. People are imagining magic AI, all of these interwoven technologies will just feel like accelerating progress, and that will just feel like life.Normalizing the extraordinary (9:46)20, 30 years ago we didn't have the internet. I think things get so normalized that this just feels like life.What you're describing is a technology that economists would call a general-purpose technology. It's a technology embedded in everything, it's everywhere in the economy, much as electricity.What you call “boring AI,” the way I think about it is: I was just reading a Wall Street Journal story about Applebee's talking about using AI for more efficient customer loyalty programs, and they would use machine vision to look at their tables to see if they were cleaned well enough between customers. That, to people, probably doesn't seem particularly science-fictional. It doesn't seem world-changing. Of course, faster growth and a more productive economy is built on those little things, but I guess I would still call those “boring AI.”What to me definitely is not boring AI is the sort of combinatorial aspect that you're talking about where you're talking about AI helping the scientific discovery process and then interweaving with other technologies in kind of the classic Paul Romer combinatorial way.I think a lot of people, if they look back at their lives 20 or 30 years ago, they would say, “Okay, more screen time, but probably pretty much the same.”I don't think they would say that. 20, 30 years ago we didn't have the internet. I think things get so normalized that this just feels like life. If you had told ourselves 30 years ago, “You're going to have access to all the world's knowledge in your pocket.” You and I are — based on appearances, although you look so youthful — roughly the same age, so you probably remember, “Hurry, it's long distance! Run down the stairs!”We live in this radical science-fiction world that has been normalized, and even the things that you are mentioning, if you see open up your newsfeed and you see that there's this been incredible innovation in cancer care, and whether it's gene therapy, or autoimmune stuff, or whatever, you're not thinking, “Oh, that was AI that did that,” because you read the thing and it's like “These researchers at University of X,” but it is AI, it is electricity, it is agriculture. It's because our ancestors learned how to plant seeds and grow plants where you're stationed and not have to do hunting and gathering that you have had this innovation that is keeping your grandmother alive for another 10 years.What you're describing is what I call “magical AI,” and that's not how it works. Some of the stuff is magical: the Jetsons stuff, and self-driving cars, these things that are just autopilot airplanes, we live in a world of magical science fiction and then whenever something shows up, we think, “Oh yeah, no big deal.” We had ChatGPT, now ChatGPT, no big deal?If you had taken your grandparents, your parents, and just said, “Hey, I'm going to put you behind a screen. You're going to have a conversation with something, with a voice, and you're going to do it for five hours,” and let's say they'd never heard of computers and it was all this pleasant voice. In the end they said, “You just had a five-hour conversation with a non-human, and it told you about everything and all of human history, and it wrote poems, and it gave you a recipe for kale mush or whatever you're eating,” you'd say, “Wow!” I think that we are living in that sci-fi world. It's going to get faster, but every innovation, we're not going to say, “Oh, AI did that.” We're just going to say, “Oh, that happened.”Engineering intelligence (13:53)I don't like the word “artificial intelligence” because artificial intelligence means “artificial human intelligence.” This is machine intelligence, which is inspired by the products of human intelligence, but it's a different form of intelligence . . .I sometimes feel in my own writing, and as I peruse the media, like I read a lot more about AI, the digital economy, information technology, and I feel like I certainly write much less about genetic engineering, biotechnology, which obviously is a key theme in your book. What am I missing right now that's happening that may seem normal five years from now, 10 years, but if I were to read about it now or understand it now, I'd think, “Well, that is kind of amazing.”My answer to that is kind of everything. As I said before, we are at the very beginning of this new era of life on earth where one species, among the billions that have ever lived, suddenly has the increasing ability to engineer novel intelligence and re-engineer life.We have evolved by the Darwinian processes of random mutation and natural selection, and we are beginning a new phase of life, a new Cambrian Revolution, where we are creating, certainly with this novel intelligence that we are birthing — I don't like the word “artificial intelligence” because artificial intelligence means “artificial human intelligence.” This is machine intelligence, which is inspired by the products of human intelligence, but it's a different form of intelligence, just like dolphin intelligence is a different form of intelligence than human intelligence, although we are related because of our common mammalian route. That's what's happening here, and our brain function is roughly the same as it's been, certainly at least for tens of thousands of years, but the AI machine intelligence is getting smarter, and we're just experiencing it.It's become so normalized that you can even ask that question. We live in a world where we have these AI systems that are just doing more and cooler stuff every day: driving cars, you talked about discoveries, we have self-driving laboratories that are increasingly autonomous. We have machines that are increasingly writing their own code. We live in a world where machine intelligence has been boxed in these kinds of places like computers, but very soon it's coming out into the world. The AI revolution, and machine-learning revolution, and the robotics revolution are going to be intersecting relatively soon in meaningful ways.AI has advanced more quickly than robotics because it hasn't had to navigate the real world like we have. That's why I'm always so mindful of not denigrating who we are and what we stand for. Four billion years of evolution is a long time. We've learned a lot along the way, so it's going to be hard to put the AI and have it out functioning in the world, interacting in this world that we have largely, but not exclusively, created.But that's all what's coming. Some specific things: 30 years from now, my guess is many people who are listening to this podcast will be fornicating regularly with robots, and it'll be totally normal and comfortable.. . . I think some people are going to be put off by that.Yeah, some people will be put off and some people will be turned on. All I'm saying is it's going to be a mix of different —Jamie, what I would like to do is be 90 years old and be able to still take long walks, be sharp, not have my knee screaming at me. That's what I would like. Can I expect that?I think this can help, but you have to decide how to behave with your personalized robot.That's what I want. I'm looking for the achievement of human suffering. Will there be a world of less human suffering?We live in that world of less human suffering! If you just look at any metric of anything, this is the best time to be alive, and it's getting better and better. . . We're living longer, we're living healthier, we're better educated, we're more informed, we have access to more and better food. This is by far the best time to be alive, and if we don't massively screw it up, and frankly, even if we do, to a certain extent, it'll continue to get better.I write about this in Superconvergence, we're moving in healthcare from our world of generalized healthcare based on population averages to precision healthcare, to predictive and preventive. In education, some of us, like myself, you have had access to great education, but not everybody has that. We're going to have access to fantastic education, personalized education everywhere for students based on their own styles of learning, and capacities, and native languages. This is a wonderful, exciting time.We're going to get all of those things that we can hope for and we're going to get a lot of things that we can't even imagine. And there are going to be very real potential dangers, and if we want to have the good story, as I keep saying, and not have the bad story, now is the time where we need to start making the real investments.Distrust of disruption (19:44)Your job is the disruption of this thing that's come before. . . stopping the advance of progress is just not one of our options.I think some people would, when they hear about all these changes, they'd think what you're telling them is “the bad story.”I just talked about fornicating with robots, it's the bad story?Yeah, some people might find that bad story. But listen, we live at an age where people have recoiled against the disruption of trade, for instance. People are very allergic to the idea of economic disruption. I think about all the debate we had over stem cell therapy back in the early 2000s, 2002. There certainly is going to be a certain contingent that, what they're going to hear what you're saying is: you're going to change what it means to be a human. You're going to change what it means to have a job. I don't know if I want all this. I'm not asking for all this.And we've seen where that pushback has greatly changed, for instance, how we trade with other nations. Are you concerned that that pushback could create regulatory or legislative obstacles to the kind of future you're talking about?All of those things, and some of that pushback, frankly, is healthy. These are fundamental changes, but those people who are pushing back are benchmarking their own lives to the world that they were born into and, in most cases, without recognizing how radical those lives already are, if the people you're talking about are hunter-gatherers in some remote place who've not gone through domestication of agriculture, and industrialization, and all of these kinds of things, that's like, wow, you're going from being this little hunter-gatherer tribe in the middle of Atlantis and all of a sudden you're going to be in a world of gene therapy and shifting trading patterns.But the people who are saying, “Well, my job as a computer programmer, as a whatever, is going to get disrupted,” your job is the disruption. Your job is the disruption of this thing that's come before. As I said at the start of our conversation, stopping the advance of progress is just not one of our options.We could do it, and societies have done it before, and they've lost their economies, they've lost their vitality. Just go to Europe, Europe is having this crisis now because for decades they saw their economy and their society, frankly, as a museum to the past where they didn't want to change, they didn't want to think about the implications of new technologies and new trends. It's why I am just back from Italy. It's wonderful, I love visiting these little farms where they're milking the goats like they've done for centuries and making cheese they've made for centuries, but their economies are shrinking with incredible rapidity where ours and the Chinese are growing.Everybody wants to hold onto the thing that they know. It's a very natural thing, and I'm not saying we should disregard those views, but the societies that have clung too tightly to the way things were tend to lose their vitality and, ultimately, their freedom. That's what you see in the war with Russia and Ukraine. Let's just say there are people in Ukraine who said, “Let's not embrace new disruptive technologies.” Their country would disappear.We live in a competitive world where you can opt out like Europe opted out solely because they lived under the US security umbrella. And now that President Trump is threatening the withdrawal of that security umbrella, Europe is being forced to race not into the future, but to race into the present.Risk tolerance (24:08). . . experts, scientists, even governments don't have any more authority to make these decisions about the future of our species than everybody else.I certainly understand that sort of analogy, and compared to Europe, we look like a far more risk-embracing kind of society. Yet I wonder how resilient that attitude — because obviously I would've said the same thing maybe in 1968 about the United States, and yet a decade later we stopped building nuclear reactors — I wonder how resilient we are to anything going wrong, like something going on with an AI system where somebody dies. Or something that looks like a cure that kills someone. Or even, there seems to be this nuclear power revival, how resilient would that be to any kind of accident? How resilient do you think are we right now to the inevitable bumps along the way?It depends on who you mean by “we.” Let's just say “we” means America because a lot of these dawns aren't the first ones. You talked about gene therapy. This is the second dawn of gene therapy. The first dawn came crashing into a halt in 1999 when a young man at the University of Pennsylvania died as a result of an error carried out by the treating physicians using what had seemed like a revolutionary gene therapy. It's the second dawn of AI after there was a lot of disappointment. There will be accidents . . .Let's just say, hypothetically, there's an accident . . . some kind of self-driving car is going to kill somebody or whatever. And let's say there's a political movement, the Luddites that is successful, and let's just say that every self-driving car in America is attacked and destroyed by mobs and that all of the companies that are making these cars are no longer able to produce or deploy those cars. That's going to be bad for self-driving cars in America — it's not going to be bad for self-driving cars. . . They're going to be developed in some other place. There are lots of societies that have lost their vitality. That's the story of every empire that we read about in history books: there was political corruption, sclerosis. That's very much an option.I'm a patriotic American and I hope America leads these revolutions as long as we can maintain our values for many, many centuries to come, but for that to happen, we need to invest in that. Part of that is investing now so that people don't feel that they are powerless victims of these trends they have no influence over.That's why all of my work is about engaging people in the conversation about how do we deploy these technologies? Because experts, scientists, even governments don't have any more authority to make these decisions about the future of our species than everybody else. What we need to do is have broad, inclusive conversations, engage people in all kinds of processes, including governance and political processes. That's why I write the books that I do. That's why I do podcast interviews like this. My Joe Rogan interviews have reached many tens of millions of people — I know you told me before that you're much bigger than Joe Rogan, so I imagine this interview will reach more than that.I'm quite aspirational.Yeah, but that's the name of the game. With my last book tour, in the same week I spoke to the top scientists at Lawrence Livermore National Laboratory and the seventh and eighth graders at the Solomon Schechter Hebrew Academy of New Jersey, and they asked essentially the exact same questions about the future of human genetic engineering. These are basic human questions that everybody can understand and everybody can and should play a role and have a voice in determining the big decisions and the future of our species.To what extent is the future you're talking about dependent on continued AI advances? If this is as good as it gets, does that change the outlook at all?One, there's no conceivable way that this is as good as it gets because even if the LLMs, large language models — it's not the last word on algorithms, there will be many other philosophies of algorithms, but let's just say that LLMs are the end of the road, that we've just figured out this one thing, and that's all we ever have. Just using the technologies that we have in more creative ways is going to unleash incredible progress. But it's certain that we will continue to have innovations across the field of computer science, in energy production, in algorithm development, in the ways that we have to generate and analyze massive data pools. So we don't need any more to have the revolution that's already started, but we will have more.Politics always, ultimately, can trump everything if we get it wrong. But even then, even if . . . let's just say that the United States becomes an authoritarian, totalitarian hellhole. One, there will be technological innovation like we're seeing now even in China, and two, these are decentralized technologies, so free people elsewhere — maybe it'll be Europe, maybe it'll be Africa or whatever — will deploy these technologies and use them. These are agnostic technologies. They don't have, as I said at the start, an inevitable outcome, and that's why the name of the game for us is to weave our best values into this journey.What is a “newnimal”? (30:11). . . we don't live in a state of nature, we live in a world that has been massively bio-engineered by our ancestors, and that's just the thing that we call life.When I was preparing for this interview and my research assistant was preparing, I said, “We have to have a question about bio-engineered new animals.” One, because I couldn't pronounce your name for these . . . newminals? So pronounce that name and tell me why we want these.It's a made up word, so you can pronounce it however you want. “Newnimals” is as good as anything.We already live in a world of bio-engineered animals. Go back 50,000 years, find me a dog, find me a corn that is recognizable, find me rice, find me wheat, find me a cow that looks remotely like the cow in your local dairy. We already live in that world, it's just people assume that our bioengineered world is some kind of state of nature. We already live in a world where the size of a broiler chicken has tripled over the last 70 years. What we have would have been unrecognizable to our grandparents.We are already genetically modifying animals through breeding, and now we're at the beginning of wanting to have whatever those same modifications are, whether it's producing more milk, producing more meat, living in hotter environments and not dying, or whatever it is that we're aiming for in these animals that we have for a very long time seen not as ends in themselves, but means to the alternate end of our consumption.We're now in the early stages xenotransplantation, modifying the hearts, and livers, and kidneys of pigs so they can be used for human transplantation. I met one of the women who has received — and seems to so far to be thriving — a genetically modified pig kidney. We have 110,000 people in the United States on the waiting list for transplant organs. I really want these people not just to survive, but to survive and thrive. That's another area we can grow.Right now . . . in the world, we slaughter about 93 billion land animals per year. We consume 200 million metric tons of fish. That's a lot of murder, that's a lot of risk of disease. It's a lot of deforestation and destruction of the oceans. We can already do this, but if and when we can grow bioidentical animal products at scale without having all of these negative externalities of whether it's climate change, environmental change, cruelty, deforestation, increased pandemic risk, what a wonderful thing to do!So we have these technologies and you mentioned that people are worried about them, but the reason people are worried about them is they're imagining that right now we live in some kind of unfettered state of nature and we're going to ruin it. But that's why I say we don't live in a state of nature, we live in a world that has been massively bio-engineered by our ancestors, and that's just the thing that we call life.Inspired by curiosity (33:42). . . the people who I love and most admire are the people who are just insatiably curious . . .What sort of forward thinkers, or futurists, or strategic thinkers of the past do you model yourself on, do you think are still worth reading, inspired you?Oh my God, so many, and the people who I love and most admire are the people who are just insatiably curious, who are saying, “I'm going to just look at the world, I'm going to collect data, and I know that everybody says X, but it may be true, it may not be true.” That is the entire history of science. That's Galileo, that's Charles Darwin, who just went around and said, “Hey, with an open mind, how am I going to look at the world and come up with theses?” And then he thought, “Oh s**t, this story that I'm coming up with for how life advances is fundamentally different from what everybody in my society believes and organizes their lives around.” Meaning, in my mind, that's the model, and there are so many people, and that's the great thing about being human.That's what's so exciting about this moment is that everybody has access to these super-empowered tools. We have eight billion humans, but about two billion of those people are just kind of locked out because of crappy education, and poor water sanitation, electricity. We're on the verge of having everybody who has a smartphone has the possibility of getting a world-class personalized education in their own language. How many new innovations will we have when little kids who were in slums in India, or in Pakistan, or in Nairobi, or wherever who have promise can educate themselves, and grow up and cure cancers, or invent new machines, or new algorithms. This is pretty exciting.The summary of the people from the past, they're kind of like the people in the present that I admire the most, are the people who are just insatiably curious and just learning, and now we have a real opportunity so that everybody can be their own Darwin.On sale everywhere The Conservative Futurist: How To Create the Sci-Fi World We Were PromisedMicro Reads▶ Economics* AI Hype Is Proving to Be a Solow's Paradox - Bberg Opinion* Trump Considers Naming Next Fed Chair Early in Bid to Undermine Powell - WSJ* Who Needs the G7? - PS* Advances in AI will boost productivity, living standards over time - Dallas Fed* Industrial Policy via Venture Capital - SSRN* Economic Sentiment and the Role of the Labor Market - St. Louis Fed▶ Business* AI valuations are verging on the unhinged - Economist* Nvidia shares hit record high on renewed AI optimism - FT* OpenAI, Microsoft Rift Hinges on How Smart AI Can Get - WSJ* Takeaways From Hard Fork's Interview With OpenAI's Sam Altman - NYT* Thatcher's legacy endures in Labour's industrial strategy - FT* Reddit vows to stay human to emerge a winner from artificial intelligence - FT▶ Policy/Politics* Anthropic destroyed millions of print books to build its AI models - Ars* Don't Let Silicon Valley Move Fast and Break Children's Minds - NYT Opinion* Is DOGE doomed to fail? Some experts are ready to call it. - Ars* The US is failing its green tech ‘Sputnik moment' - FT▶ AI/Digital* Future of Work with AI Agents: Auditing Automation and Augmentation Potential across the U.S. Workforce - Arxiv* Is the Fed Ready for an AI Economy? - WSJ Opinion* How Much Energy Does Your AI Prompt Use? I Went to a Data Center to Find Out. - WSJ* Meta Poaches Three OpenAI Researchers - WSJ* AI Agents Are Getting Better at Writing Code—and Hacking It as Well - Wired* Exploring the Capabilities of the Frontier Large Language Models for Nuclear Energy Research - Arxiv▶ Biotech/Health* Google's new AI will help researchers understand how our genes work - MIT* Does using ChatGPT change your brain activity? Study sparks debate - Nature* We cure cancer with genetic engineering but ban it on the farm. - ImmunoLogic* ChatGPT and OCD are a dangerous combo - Vox▶ Clean Energy/Climate* Is It Too Soon for Ocean-Based Carbon Credits? - Heatmap* The AI Boom Can Give Rooftop Solar a New Pitch - Bberg Opinion▶ Robotics/Drones/AVs* Tesla's Robotaxi Launch Shows Google's Waymo Is Worth More Than $45 Billion - WSJ* OpenExo: An open-source modular exoskeleton to augment human function - Science Robotics▶ Space/Transportation* Bezos and Blue Origin Try to Capitalize on Trump-Musk Split - WSJ* Giant asteroid could crash into moon in 2032, firing debris towards Earth - The Guardian▶ Up Wing/Down Wing* New Yorkers Vote to Make Their Housing Shortage Worse - WSJ* We Need More Millionaires and Billionaires in Latin America - Bberg Opinion▶ Substacks/Newsletters* Student visas are a critical pipeline for high-skilled, highly-paid talent - AgglomerationsState Power Without State Capacity - Breakthrough JournalFaster, Please! is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit fasterplease.substack.com/subscribe

Top officials gave updated damage assessments on the Trump administration's historic bunker bust of Iran's nuclear program. On Thursday, both the President and U.S. Defense Secretary Hegseth pushed back on media reports downplaying the efficacy of the strikes, emphasizing this was a "highly successful mission." FOX News Sunday anchor Shannon Bream joins to discuss the latest updates on Iran's nuclear capabilities, New York's Mayoral Democratic primary, and a Supreme Court ruling on funding to Planned Parenthood. Malaria kills around 600,000 people each year according to the World Health Organization, with mosquitoes largely responsible for spreading this deadly disease. Futurist Jamie Meltz, author of “Superconvergence: How the Genetics, Biotech, and AI Revolutions Will Transform our Lives,” joins the podcast to explore the scientific possibility of editing mosquitoes' DNA in order to eliminate or genetically modify the entire species, while warning of the ethical and ecological risks when altering complex natural systems. Don't miss the good news with Tonya J. Powers. Plus, commentary by Brian Kilmeade, Host of One Nation with Brian Kilmeade and The Brian Kilmeade Show. Photo Credit: AP Learn more about your ad choices. Visit podcastchoices.com/adchoices

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Former FDA official Peter Marks criticized the agency's new risk-based COVID-19 vaccine framework, stating it contradicts the administration's transparency and science standards. The CDC's advisory committee recommended Merck's infant RSV vaccine, and Novavax's approval delay raised concerns about politicization of drug approval processes. Lilly's Verve deal revealed regulatory turmoil following Marks' resignation. Meanwhile, Trump's CDC pick supports vaccine safety, Novartis made a large bet on cardiovascular disease targets, and RFK cut US funding from vaccine alliance Gavi. The biopharma industry is hiring less international talent, and pharma companies face challenges with failed immuno-oncology projects. Evotec is hosting a webinar on preserving quality in the pharmaceutical industry.

Top officials gave updated damage assessments on the Trump administration's historic bunker bust of Iran's nuclear program. On Thursday, both the President and U.S. Defense Secretary Hegseth pushed back on media reports downplaying the efficacy of the strikes, emphasizing this was a "highly successful mission." FOX News Sunday anchor Shannon Bream joins to discuss the latest updates on Iran's nuclear capabilities, New York's Mayoral Democratic primary, and a Supreme Court ruling on funding to Planned Parenthood. Malaria kills around 600,000 people each year according to the World Health Organization, with mosquitoes largely responsible for spreading this deadly disease. Futurist Jamie Meltz, author of “Superconvergence: How the Genetics, Biotech, and AI Revolutions Will Transform our Lives,” joins the podcast to explore the scientific possibility of editing mosquitoes' DNA in order to eliminate or genetically modify the entire species, while warning of the ethical and ecological risks when altering complex natural systems. Don't miss the good news with Tonya J. Powers. Plus, commentary by Brian Kilmeade, Host of One Nation with Brian Kilmeade and The Brian Kilmeade Show. Photo Credit: AP Learn more about your ad choices. Visit podcastchoices.com/adchoices

Cheryl Reicin, the co-chair of the life sciences group at Mintz, discusses how she became a biotech lawyer and why observing the Sabbath has been good for her as a lawyer. 

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.The CDC's new vaccine advisors are meeting with an unexpected agenda today, including discussions on topics such as Sanofi and Gilead's protein degrader deals, the FDA's review of Sarepta's gene therapy, and a contentious hearing with RFK Jr. over vaccines. The meeting marks the beginning of a new era for the influential vaccine committee. The FDA has named a psychedelic proponent as CDER deputy director, while Nektar has declared a Phase IIb win for eczema treatment. Experts say conflicts of interest among axed ACIP members are a "red herring," and the pharma industry is facing turmoil in failed immuno-oncology projects. Prescription drug sales are projected to hit $1.75 trillion by 2030, thanks to GLP-1s. Transitioning to the next news, a major pharmaceutical company has announced a breakthrough in cancer research, potentially changing the landscape of treatment options for patients worldwide. This development comes at a time when the industry is seeing significant advancements in personalized medicine and targeted therapies. Moving on to regulatory updates, the FDA has recently approved a new drug for a rare disease, providing hope for patients who previously had limited treatment options. This decision showcases the agency's commitment to expediting the approval process for innovative therapies that address unmet medical needs. In other news, a biotech startup has secured funding for its groundbreaking technology that aims to revolutionize drug delivery methods. This investment highlights the growing interest in novel approaches to drug development and underscores the importance of innovation in the industry.Wrapping up today's episode, we take a look at the latest trends in digital health, with companies leveraging artificial intelligence and big data analytics to improve patient outcomes and streamline healthcare delivery. These technological advancements have the potential to transform the way healthcare is delivered and pave the way for a more efficient and patient-centric system. That's all for today's episode of Pharma and Biotech daily. Stay tuned for more updates on the latest developments in the pharmaceutical and biotechnology sectors.

In this episode of Data in Biotech, Ross Katz sits down with Kenny Workman, co-founder and CTO of LatchBio, to unpack how biotech's data infrastructure must evolve to meet the demands of next-gen assays. From scalable workflows to high-performance visualization tools, Kenny breaks down the shift from traditional biotech to a future defined by data-driven research and agile cloud platforms. ​​What You'll Learn in This Episode: Why spatial biology and high-throughput assays require new data infrastructure strategiesHow LatchBio's five core components streamline molecular data processingThe challenges of selling into biotech vs. solution providers and the strategic pivot LatchBio made to address thisHow large language models are revolutionizing public data curation for biotechsWhy scientific innovation demands better tech adoption across the industry Meet Our Guest Kenny Workman is co-founder and CTO of LatchBio, a company transforming biological data infrastructure. A UC Berkeley alum, Kenny brings deep expertise in bioengineering, machine learning, and cloud systems. He was named to Forbes' 2023 "30 Under 30" list for his contributions to computational biology. About The Host Ross Katz is Principal and Data Science Lead at CorrDyn. Ross specializes in building intelligent data systems that empower biotech and healthcare organizations to extract insights and drive innovation. Connect with Our Guest: Sponsor: CorrDyn, a data consultancyFind out more about Latch BioConnect with Kenny Workman  on LinkedIn  Connect with Us: Follow the podcast for more insightful discussions on the latest in biotech and data science.Subscribe and leave a review if you enjoyed this episode!Connect with Ross Katz on LinkedIn Sponsored by… This episode is brought to you by CorrDyn, the leader in data-driven solutions for biotech and healthcare. Discover how CorrDyn is helping organizations turn data into breakthroughs at CorrDyn.

Are you a biotech leader battling overload, stress, or even burnout? In this episode, co-hosts James Zanewicz, JD, LLM, RTTP, and Elaine Hamm, PhD, sit down with returning guest Carlo Odicino, MBA, founder and CEO of One Team Partners, for a powerful and realistic discussion about navigating the pressures of leadership in a high-stakes industry. From battling overwhelming priorities to preserving your health and well-being while growing your business, Carlo offers hard-won strategies for turning chaos into calm and turning pressure into progress. In this episode, you'll discover: The most common contributors to burnout for CEOs – and strategies to avoid them. Why self-care and delegation are essential for strong, sustainable leadership. How routines, healthy habits, and re-framing your choices can enable you to withstand stress and keep innovating. Get ready to lead with clarity, keep your cool, and chart a path forward—no matter what the market throws at you. Links: Connect with Carlo Odicino, MBA, and check out One Team Partners. Connect with Elaine Hamm, PhD, and James Zanewicz, JD, LLM, RTTP, and learn about Tulane Medicine Business Development and the School of Medicine. Connect with Ian McLachlan, BIO from the BAYOU producer. Check out BIO on the BAYOU and make plans to attend October 28 & 29, 2025. And click here to apply for a startup pitch slot. Learn more about BIO from the BAYOU - the podcast. Bio from the Bayou is a podcast that explores biotech innovation, business development, and healthcare outcomes in New Orleans & The Gulf South, connecting biotech companies, investors, and key opinion leaders to advance medicine, technology, and startup opportunities in the region.

Risa Arin doesn't just talk about health literacy. She built the damn platform. As founder and CEO of XpertPatient.com (yes, expert with no E), Risa's taking a wrecking ball to how cancer education is delivered. A Cornell alum, cancer caregiver, and ex-agency insider who once sold Doritos to teens, she now applies that same marketing muscle to helping patients actually understand the garbage fire that is our healthcare system. We talk about why she left the “complacent social safety” of agency life, how her mom unknowingly used her own site during treatment, what it's like to pitch cancer education after someone pitches warm cookies, and why healthcare should come with a map, a translator, and a refund policy. Risa brings data, chutzpah, and Murphy Brown energy to the conversation—and you'll leave smarter, angrier, and maybe even a little more hopeful.RELATED LINKS• XpertPatient.com• Risa Arin on LinkedIn• XpertPatient & Antidote Partnership• XpertPatient Featured on KTLA• 2024 Health Award BioFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Check out the TIES Sales Showdown at www.tx.ag/TIESVisit The Sales Lab at https://thesaleslab.org and check out all our guests' recommended readings at https://thesaleslab.org/reading-listTo listen to The Sales Lab Podcast on your favorite apps, visit https://thesaleslab.simplecast.com/ and select your preferred method of listening.Connect with us on Facebook at https://www.facebook.com/saleslabpodcastConnect with us on Linkedin at https://www.linkedin.com/company/thesaleslabSubscribe to The Sales Lab channel on YouTube at  https://www.youtube.com/channel/UCp703YWbD3-KO73NXUTBI-Q 

On this episode of Digital Squared, Tom is talking to Dr. Harold Schmitz. Harold has had an incredible career spanning academia, industry, and venture capital, with a focus on food science, nutrition, and innovation. He spent 25 years at Mars Incorporated, including as their Chief Science Officer, where he led groundbreaking research on cocoa and chocolate. Now Harold is a co-founding partner at The March Group, a venture capital firm investing in food tech startups. He's also a Senior Scholar at UC Davis, working to bridge the gap between industry and academia. Harold brings a wealth of knowledge about the food industry, emerging technologies, and how to drive meaningful innovation. 

What if the key to transforming the global protein system lies in technology we've had for decades?Stephan van Sint Fiet, CEO of Vivici, reveals how industrial biotech is stepping off the lab bench and onto supermarket shelves — using precision fermentation to create dairy proteins ready for scale.In this episode, we unpack Vivici's strategic focus on high-value proteins like beta-lactoglobulin, their approach to reaching cost parity, and why trust, transparency, and taste are critical for mainstream adoption.Learn how a tried-and-tested biotech playbook is helping rewrite the rules of sustainable food production. Tune in to hear how decades-old biotech is poised to reshape the way the world consumes protein.---Hey Climate Tech enthusiasts! Searching for new podcasts on sustainability? Check out the Leaders on a Mission podcast, where I interview climate tech leaders who are shaking up the industry and bringing us the next big thing in sustainable solutions. Join me for a deep dive into the future of green innovation exploring the highs, lows, and everything in between of pioneering new technologies.Get an exclusive insight into how these leaders started up their journey, and how their cutting edge products will make a real impact. Tune in on…YouTube: https://www.youtube.com/@leadersonamissionNet0Spotify: https://open.spotify.com/show/7o41ubdkzChAzD9C53xH82Apple Podcasts: https://podcasts.apple.com/us/podcast/leaders-on-a-mission/id1532211726…to listen to the latest episodes!1:06 — Why biotech drew Stephan in  2:47 — The protein demand crisis  7:01 — Why Vivici chose dairy  9:14 — Tackling the scale-up challenge  14:01 — The power of beta-lactoglobulin  17:24 — Competing with cheap proteins  20:47 — Key milestones to date  30:39 — “We're not reinventing this”  34:21 — Cracking consumer adoptionUseful links: Vivici website: https://www.vivici.com            Vivici's LinkedIn: https://www.linkedin.com/company/viviciprotein/  Stephan van Sint Fiet LinkedIn: https://www.linkedin.com/in/stephanvansintfiet/Leaders on a Mission website: https://cs-partners.net/podcasts/Simon Leich's LinkedIn: https://www.linkedin.com/in/executive-talent-headhunter-agtech-foodtech-agrifoodtech-agritech/

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. The FDA's Center for Drug Evaluation and Research (CDER) head, Jacqueline Corrigan-Curay, is leaving the agency in July, becoming the latest in a series of FDA leaders to depart. Eli Lilly is facing concerns about gastrointestinal side effects for their weight loss pill, Orfoglipron, despite brushing off these worries. Vertex's cell therapy for diabetes shows promise, but questions remain about its market potential. HHS Secretary Robert F. Kennedy Jr. has restacked the CDC's vaccine advisory committee, claiming conflicts of interest within the previous group, which experts argue may impact the committee's apolitical nature. Prothena has downsized following a failure in an Al amyloidosis trial, and Novavax is adapting to regulatory uncertainty. Overall, the FDA is experiencing significant turnover in leadership, and challenges persist in drug development and regulation.

On this episode of Guest Commentary, a Philly-born scientist explains what is actually at stake for the town she loves

We love to hear from our listeners. Send us a message. On this week's episode, Barry Quart, CEO of Connect Biopharma, weighs in on the current state of engagement between drug developers and the FDA, and how that key relationship continues to evolve under new leadership. Barry also discusses moving the company from China to San Diego, why a U.S. financial reporting structure helps attract investors, and how Connect is finding the white spaces in respiratory disease -- the company's lead candidate is a biologic drug targeting acute asthma and COPD exacerbations. This episode of the Business of Biotech is brought to you by Ecolab.Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.Nicole Verdun has exited the FDA as CBER director, allowing Vinay Prasad to consolidate power within the agency. Prasad is seen as a stabilizing and trustworthy figure within the rapidly changing FDA, especially since the departure of Peter Marks in late March. Novavax is adapting to regulatory uncertainty following the delayed approval of its next-generation COVID-19 vaccine. The company is relying on agility and a diverse pipeline to navigate changing regulations. Additionally, the FDA has frozen trials shipping cells to countries like China due to new export control policies. Exemptions have allowed companies to ship biological materials overseas, but this practice is now being restricted. Zealand's GLP-1/GLP-2 drug has shown promising results in weight loss trials, with analysts believing there is potential for further improvement. Intellia Therapeutics aims to transform the lives of people with severe diseases through genome editing treatments. Overall, the biotech industry is facing various challenges and changes, requiring companies to stay adaptable and innovative.

Aktien hören ist gut. Aktien kaufen ist besser. Bei unserem Partner Scalable Capital geht's unbegrenzt per Trading-Flatrate oder regelmäßig per Sparplan. Alle weiteren Infos gibt's hier: scalable.capital/oaws. Aktien + Whatsapp = Hier anmelden. Lieber als Newsletter? Geht auch. Das Buch zum Podcast? Jetzt lesen. Circle boomt und wir checken's nicht. Brad Jacobs und QXO streiten sich mit Home Depot um GMS. Maserati könnt ihr kaufen. Apple könnte Perplexity kaufen. Wix hat Base44 gekauft. Softbank, Foxconn & NVIDIA planen Zukunft. Trump greift den Iran an. Der Markt für Lachs soll bis 2034 über 40 Mrd. $ schwer sein. Schon heute kommt das Angebot der extrem hohen Nachfrage kaum hinterher. Akva (WKN: A0LEQU) will das lösen. 7% Dividende bei einer Biotech-Wette? Alexandria Real Estate (WKN: 907179) macht's möglich. Diesen Podcast vom 23.06.2025, 3:00 Uhr stellt dir die Podstars GmbH (Noah Leidinger) zur Verfügung.

On this week's Tech Nation, Moira speaks with Biotech Entrepreneur, Dr. Jake Glanville, Founder, Chair and CEO of Centivax, gives us the insider's view of the first real breakthrough in snake antivenom in 125 years, all thanks to a man who's been bitten by over 200 venomous snakes. Then, Robert Blum, CEO of CytoKinetics, shares the latest in hear failure treatment and what it could mean for extending quality of life.

Dr. Jamie Wells is back—and this time, she brought a book. We cover everything from biomedical design screwups to the glorified billing software known as the EHR. Jamie's new book, A Clinical Lens on Pediatric Engineering, is a masterclass in what happens when you stop treating kids like small, drunk adults and start designing medicine around actual human factors. We talk about AI in pediatric radiology, why drug repurposing might save lives faster than biotech IPOs, and the absurdity of thinking one-size-fits-all in healthcare still works.Jamie's a former physician, a health policy disruptor, a bioethicist, an MIT director, and a recovering adjunct professor. She's also a unicorn. We dig into the wonk, throw shade at bad design, and channel our inner Lisa Simpsons. This one's for anyone who ever wondered why kids' hospitals feel like hell and why “make it taste like bubblegum” might be the most important clinical innovation of all time. You'll laugh, you'll learn, and you might get angry enough to fix something.RELATED LINKSJamie Wells on LinkedInBook: A Clinical Lens on Pediatric Engineering (Amazon)Book on SpringerDrexel BioMed ProfileGlobal Blockchain Business CouncilJamie's HuffPost ArticlesFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Origins hosts Nick Chirls, GP at Asylum Ventures and Beezer Clarkson,  LP at Sapphire Partners and co-founder of OpenLP, unpack their conversation with Zach Weinberg, Co-Founder and CEO of Curie.Bio. They discuss the “innovation energy” that drives new breakthroughs and take a closer look at Sapphire's approach to biotech investing.Learn more about Sapphire Partners: sapphireventures.com/sapphire-partnersLearn more about OpenLP: openlp.vcLearn more about Asylum Ventures: asylum.vcLearn more about Curie.Bio: curie.bioSubscribe to the OpenLP newsletter for a monthly roundup of the latest venture insights, including the newest Origins episodes, delivered straight to your inbox.CHAPTERS:0:00 - Welcome to Origins1:28 -Building Something That Wouldn't Exist Otherwise4:27 - What's Sapphire Doing in BioTech?8:38 - The Market & BioTech10:05 - "Vitamin O"

We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Tom Wells, Director of Life Sciences at 4C Associates, reveals why -- and how -- smart procurement practices can make or break emerging biotech companies during critical growth stages. Tom shares insights into procurement tools and strategies that can deliver breakthrough solutions, how poor procurement practices can damage investor confidence, and why thinking about procurement as the front end of demand flow, not the back end of supply chain, can help drug developers avoid costly mistakes. This episode of the Business of Biotech is brought to you by Ecolab. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

Plus: Oracle posts strong quarterly results boosted by its AI investments. Biotech company BioNTech acquires CureVac. Adobe raises its full-year outlook after posting higher-than-expected earnings. Ariana Aspuru hosts.  Sign up for the WSJ's free What's News newsletter.  Learn more about your ad choices. Visit megaphone.fm/adchoices

To Sign up for our Patreon go to-> Patreon.com/cultofconspiracypodcast10% OFF Rife Machine---> https://rifemachine.myshopify.com/?rfsn=7689156.6a9b5cMeta Mysteries Podcast---> https://open.spotify.com/show/6IshwF6qc2iuqz3WTPz9Wv?si=3a32c8f730b34e79http://Brogrove.comCajun Knight Youtube Channel---> https://www.youtube.com/@Cajunknight50% OFF Adam&Eve products---> :adameve.com (promo code : CULT)10%OFF Orgonite ! ---> https://oregon-ite.com/?sca_ref=5029405.hji3fNHxUdTo Sign up for our Rokfin go to --> Rokfin.com/cultofconspiracyBecome a supporter of this podcast: https://www.spreaker.com/podcast/cult-of-conspiracy--5700337/support.